News Doubts over BACE drugs after Merck ends Alzheimer's trial Decision comes a year after Merck axed EPOCH verubecestat trial
News Lilly aims for new indication for Taltz Eli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and put pressure on Novartis’ rival IL-17a drug, Cosentyx.
News Greece to probe claims that Novartis bribed former leaders Scandal could be biggest in country's history, says politician
News Vertex's latest cystic fibrosis combination approved in US Vertex’s quest to treat a wider group of patients with cystic fibrosis (CF) continues after the FDA approved its latest combination therapy, Symdeko.
News Ramaswamy's Roivant signs diabetes drug deal with Poxel Biotech entrepreneur hopes to bounce back from Alzheimer's disappointment
News Boehringer latest to axe Alzheimer's drug Company will trial BI 409306 in schizophrenia instead.
News Kennedy changes vaccine panel charter after legal setback A change to the ACIP charter has raised concerns of even greater political influence over the vaccine panel by HHS Secretary Kennedy.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
